^
Association details:
| Biomarker: | EGFR exon 19 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | cisplatin (DNA synthesis inhibitor) + gefitinib (EGFR inhibitor) + docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Curative treatment in EGFR mt+ NSCLC stage III by induction TKI-chemotherapy combination: Feasibility and outcome in 7 cases
Published date:
09/14/2020
Excerpt:
7/7 patients had adenocarcinoma, 5 with EGFR exon 19 and 2 with EGFR L858R. Patients received erlotinib (n=2) or gefitinib (n=5) for 10 days followed by TKI in combination with chemotherapy (docetaxel/cisplatin (n=4), paclitaxel/carboplatin (n=3)) for 3 cycles. Median OS of the 7 patients was 51 months and median PFS was 17 months. In conclusion 1st generation TKI-chemotherapy induction in EGFR mt+ NSCLC is feasible...
